← Leaderboards
Jesse Bruce Owens
University Of Hawaii At Manoa
$3,912,016
Attributed
$3,912,016
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $664.9K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,912,016 · 4
By mechanism
R01$2,836,279 · 2
P20$686,612 · 1
R21$389,125 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Hawaii At Manoa
Same institution · by research overlap
- Stefan Moisyadi$6,527,326
- Pratibha V Nerurkar$842,915
- Andrew Kekupa'a Knutson$333,052
Others in their field
Other Emerging Leaders on “Genome”
- Leonard Freedman · Leidos Biomedical Research, Inc.$405,398,682
- Scott Topper · Broad Institute, Inc.$153,234,573
- Lynn Briscoe · Leidos Biomedical Research, Inc.$137,892,657
- Leonard Freedmand · Leidos Biomedical Research, Inc.$96,686,407
- Dwayne Forquer · Leidos Biomedical Research, Inc.$50,844,487
- Scott Andrew Sutherland · Vignet, Inc.$37,105,117
Research focus
GenomeExperimental StudyGenesTissuesInnovationVectorCellsRepairedGenome EditingSiteGenetic DiseasesHuman GenomeGene DeliveryGenomicsMouse ModelMutationDna IntegrationInterphase CellClustered Regularly Interspaced Short Palindromic RepeatsBacteriophagesEvolutionGene TherapyDirected Molecular EvolutionMalignant Neoplasms
Grant awards (10)
Development of a Targetable Transposase Platform for Precision Gene Integration in Human Cells$522,764
R01 · FY2025 · GM · contact PI
Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome.$570,410
R01 · FY2024 · EB · contact PI
Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome.$582,050
R01 · FY2023 · EB · contact PI
Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome.$586,342
R01 · FY2022 · EB · contact PI
Directed evolution of a sequence-specific targeting technology for therapeutic gene delivery to the human genome.$574,713
R01 · FY2021 · EB · contact PI
Assessing lifespan and aging phenotypes resulting from FoxO3 induction using mouse models$90,145
P20 · FY2021 · GM · contact PI
Assessing lifespan and aging phenotypes resulting from FoxO3 induction using mouse models$286,775
P20 · FY2020 · GM · contact PI
Development of a novel genome targeting technology using rational design and continuous evolution.$212,250
R21 · FY2020 · GM · contact PI
Assessing lifespan and aging phenotypes resulting from FoxO3 induction using mouse models$309,692
P20 · FY2019 · GM · contact PI
Development of a novel genome targeting technology using rational design and continuous evolution.$176,875
R21 · FY2019 · GM · contact PI